U.S. markets closed

PharmAust Limited (PAA.AX)

ASX - ASX Delayed Price. Currency in AUD
Add to watchlist
0.0850+0.0010 (+1.19%)
At close: 03:11PM AEST

PharmAust Limited

5/3 Brodie Hall Drive
Bentley, WA 6102
61 8 9202 6814

Full Time Employees

Key Executives

NameTitlePayExercisedYear Born
Dr. Roger Aston B.Sc., BSc (Hons), Ph.D.Exec. Chairman & Acting CEO284.7kN/A1956
Mr. Sam Michael Wright A.C.I.S., ACIS, AFin, DipAcc, M.A.I.C.D., MAICDFin. Director, Company Sec. & Non-Exec. Director138kN/A1978
Dr. Richard MollardChief Scientific Officer262.8kN/AN/A
Dr. Martine KeenanChief Scientific Officer & Exec. Director of Epichem Pty Ltd158.23kN/AN/A
Mr. Robert Charles Bishop LLB (Hons)Exec. Director140.16kN/AN/A
Dr. Gary PittHead of ChemistryN/AN/AN/A
Dr. James RixsonHead of ProductionN/AN/AN/A
Amounts are as of December 31, 2021 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in AUD.


PharmAust Limited, a clinical-stage company, develops targeted cancer therapeutics for humans and animals. The company develops drugs for the treatment of various cancers, and viral and neurological diseases. Its lead candidate is Monepantel (MPL), a small molecule drug for the treatment of cancer. PharmAust has completed Phase 1 clinical trials with monepantel in human and dog diagnosed with solid tumors, as well as initiated a Phase 2 pilot study in dogs diagnosed with Lymphoma. The company also provides products and services in synthetic and medicinal chemistry to the drug discovery and pharmaceutical industries worldwide. The company has a research agreement with the Walter and Eliza Hall Institute to investigate the effects of MPL upon human T-lymphotrophic virus-1 (HTLV-1) infections in vitro. It serves drug discovery and pharmaceutical industries. PharmAust Limited was incorporated in 2000 and is based in Bentley, Australia.

Corporate Governance

PharmAust Limited’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.